title: Treatment of CAPD-peritonitis due to glycopeptide-resistant Enterococcus faecium with quinupristin/dalfopristin.
authors.forename: W A
authors.initials: WA
authors.lastname: Lynn
authors.forename: E
authors.initials: E
authors.lastname: Clutterbuck
authors.forename: S
authors.initials: S
authors.lastname: Want
authors.forename: V
authors.initials: V
authors.lastname: Markides
authors.forename: S
authors.initials: S
authors.lastname: Lacey
authors.forename: T R
authors.initials: TR
authors.lastname: Rogers
authors.forename: J
authors.initials: J
authors.lastname: Cohen
mesh_terms: D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use*; D016984:Enterococcus faecium / Q000187:drug effects; D005260:Female; D016908:Gram-Positive Bacterial Infections / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D010531:Peritoneal Dialysis, Continuous Ambulatory / Q000009:adverse effects*; D010538:Peritonitis / Q000188:drug therapy* / Q000382:microbiology; D014769:Virginiamycin / Q000627:therapeutic use*
chemical_list: D000900:Anti-Bacterial Agents; D014769:Virginiamycin; C062940:quinupristin-dalfopristin